Class information for:
Level 1: DABIGATRAN//RIVAROXABAN//APIXABAN

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
58 4699 37.5 84%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
8 4 CARDIAC & CARDIOVASCULAR SYSTEM//PERIPHERAL VASCULAR DISEASES//CARDIOL 1276458
11 3       ATRIAL FIBRILLATION//CARDIAC & CARDIOVASCULAR SYSTEM//CATHETER ABLATION 130936
171 2             ATRIAL FIBRILLATION//CATHETER ABLATION//DABIGATRAN 22370
58 1                   DABIGATRAN//RIVAROXABAN//APIXABAN 4699

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 DABIGATRAN authKW 3178531 13% 79% 617
2 RIVAROXABAN authKW 3025972 13% 74% 630
3 APIXABAN authKW 2400624 9% 86% 432
4 ATRIAL FIBRILLATION authKW 1424318 38% 12% 1782
5 EDOXABAN authKW 1110787 4% 93% 184
6 ANTICOAGULANTS authKW 644187 13% 16% 630
7 WARFARIN authKW 609207 13% 16% 595
8 FACTOR XA INHIBITOR authKW 575259 4% 47% 188
9 DABIGATRAN ETEXILATE authKW 536375 2% 81% 102
10 CITY HOSP address 509718 7% 23% 347

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Peripheral Vascular Diseases 29695 24% 0% 1111
2 Cardiac & Cardiovascular System 27593 31% 0% 1436
3 Hematology 17112 19% 0% 887
4 Medicine, General & Internal 5599 17% 0% 804
5 Pharmacology & Pharmacy 2011 14% 0% 674
6 Clinical Neurology 642 7% 0% 312
7 Geriatrics & Gerontology 498 2% 0% 95
8 Health Care Sciences & Services 482 3% 0% 122
9 Primary Health Care 285 1% 0% 41
10 Critical Care Medicine 237 2% 0% 82

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CITY HOSP 509718 7% 23% 347
2 AALBORG THROMBOSIS UNIT 410065 2% 68% 93
3 CARDIOVASC SCI 124938 8% 5% 399
4 UPPSALA CLIN 63979 2% 13% 75
5 GLOBAL CLIN DEV MED AFFAIRS 52619 0% 90% 9
6 AALBORG AF STUDY GRP 45461 0% 50% 14
7 PHARMACOMETRY 38978 0% 100% 6
8 ATRIAL FIBRILLAT STUDY GRP 34642 0% 67% 8
9 CARDIOL 33561 19% 1% 910
10 THROMBOSIS ATHEROSCLEROSIS 29381 1% 18% 25

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 JOURNAL OF THROMBOSIS AND THROMBOLYSIS 46250 2% 6% 115
2 THROMBOSIS AND HAEMOSTASIS 30464 5% 2% 217
3 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 23364 3% 3% 119
4 AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS 14772 1% 7% 31
5 THROMBOSIS RESEARCH 13330 3% 1% 146
6 CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES 12581 1% 5% 37
7 EUROPACE 10792 2% 2% 74
8 INTERNATIONAL JOURNAL OF CARDIOLOGY 7606 3% 1% 119
9 JOURNAL OF THE AMERICAN HEART ASSOCIATION 7588 1% 3% 45
10 STROKE 6919 3% 1% 125

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class		 LCSH search Wikipedia search
1 DABIGATRAN 3178531 13% 79% 617 Search DABIGATRAN Search DABIGATRAN
2 RIVAROXABAN 3025972 13% 74% 630 Search RIVAROXABAN Search RIVAROXABAN
3 APIXABAN 2400624 9% 86% 432 Search APIXABAN Search APIXABAN
4 ATRIAL FIBRILLATION 1424318 38% 12% 1782 Search ATRIAL+FIBRILLATION Search ATRIAL+FIBRILLATION
5 EDOXABAN 1110787 4% 93% 184 Search EDOXABAN Search EDOXABAN
6 ANTICOAGULANTS 644187 13% 16% 630 Search ANTICOAGULANTS Search ANTICOAGULANTS
7 WARFARIN 609207 13% 16% 595 Search WARFARIN Search WARFARIN
8 FACTOR XA INHIBITOR 575259 4% 47% 188 Search FACTOR+XA+INHIBITOR Search FACTOR+XA+INHIBITOR
9 DABIGATRAN ETEXILATE 536375 2% 81% 102 Search DABIGATRAN+ETEXILATE Search DABIGATRAN+ETEXILATE
10 ORAL ANTICOAGULANTS 465678 4% 37% 192 Search ORAL+ANTICOAGULANTS Search ORAL+ANTICOAGULANTS

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 HEIDBUCHEL, H , VERHAMME, P , ALINGS, M , ANTZ, M , DIENER, HC , HACKE, W , OLDGREN, J , SINNAEVE, P , CAMM, AJ , KIRCHHOF, P , (2015) UPDATED EUROPEAN HEART RHYTHM ASSOCIATION PRACTICAL GUIDE ON THE USE OF NON-VITAMIN K ANTAGONIST ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION.EUROPACE. VOL. 17. ISSUE 10. P. 1467 -1507 129 61% 129
2 CAMM, AJ , LIP, GYH , DE CATERINA, R , SAVELIEVA, I , ATAR, D , HOHNLOSER, SH , HINDRICKS, G , KIRCHHOF, P , BAX, JJ , BAUMGARTNER, H , ET AL (2012) 2012 FOCUSED UPDATE OF THE ESC GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION.EUROPEAN HEART JOURNAL. VOL. 33. ISSUE 21. P. 2719-2747 84 48% 1150
3 CHAN, NC , EIKELBOOM, JW , WEITZ, JI , (2016) EVOLVING TREATMENTS FOR ARTERIAL AND VENOUS THROMBOSIS ROLE OF THE DIRECT ORAL ANTICOAGULANTS.CIRCULATION RESEARCH. VOL. 118. ISSUE 9. P. 1409 -1424 100 84% 6
4 LIP, GYH , LANE, DA , (2015) STROKE PREVENTION IN ATRIAL FIBRILLATION A SYSTEMATIC REVIEW.JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. VOL. 313. ISSUE 19. P. 1950 -1962 88 81% 41
5 ALAMNEH, EA , CHALMERS, L , BEREZNICKI, LR , (2016) SUBOPTIMAL USE OF ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION: HAS THE INTRODUCTION OF DIRECT ORAL ANTICOAGULANTS IMPROVED PRESCRIBING PRACTICES?.AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. VOL. 16. ISSUE 3. P. 183 -200 110 94% 0
6 FRANCHINI, M , BONFANTI, C , MANNUCCI, PM , (2015) MANAGEMENT OF BLEEDING ASSOCIATED WITH NEW ORAL ANTICOAGULANTS.SEMINARS IN THROMBOSIS AND HEMOSTASIS. VOL. 41. ISSUE 7. P. 788 -801 102 94% 5
7 FAVALORO, EJ , LIPPI, G , (2015) LABORATORY TESTING IN THE ERA OF DIRECT OR NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS: A PRACTICAL GUIDE TO MEASURING THEIR ACTIVITY AND AVOIDING DIAGNOSTIC ERRORS.SEMINARS IN THROMBOSIS AND HEMOSTASIS. VOL. 41. ISSUE 2. P. 208 -227 97 96% 6
8 RUFF, CT , GIUGLIANO, RP , BRAUNWALD, E , HOFFMAN, EB , DEENADAYALU, N , EZEKOWITZ, MD , CAMM, AJ , WEITZ, JI , LEWIS, BS , PARKHOMENKO, A , ET AL (2014) COMPARISON OF THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS WITH WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION: A META-ANALYSIS OF RANDOMISED TRIALS.LANCET. VOL. 383. ISSUE 9921. P. 955-962 34 89% 522
9 BLANN, A , (2016) NON-VITAMIN K ORAL ANTICOAGULANTS (NOACS) A REVIEW OF CLINICAL MANAGEMENT AND LABORATORY ISSUES.CURRENT VASCULAR PHARMACOLOGY. VOL. 14. ISSUE 3. P. 220 -236 109 89% 0
10 ALBERTS, MJ , EIKELBOOM, JW , HANKEY, GJ , (2012) ANTITHROMBOTIC THERAPY FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION.LANCET NEUROLOGY. VOL. 11. ISSUE 12. P. 1066 -1081 102 85% 37

Classes with closest relation at Level 1


Rank Class id link
1 21109 TRIPLE ANTITHROMBOTIC THERAPY//ATRIAL INFARCTION//ANTITHROMBOTIC REGIMENS
2 2259 LEFT ATRIAL APPENDAGE//ATRIAL FIBRILLATION//LEFT ATRIAL APPENDAGE CLOSURE
3 15872 PALPITATIONS//INSERTABLE CARDIAC MONITOR//ATRIAL FIBRILLATION
4 5951 INTERNATIONAL NORMALIZED RATIO//PROTHROMBIN TIME//INR
5 1469 ATRIAL FIBRILLATION//DRONEDARONE//CARDIOVERSION
6 19162 PROTHROMBIN COMPLEX CONCENTRATE//ANTICOAGULATION REVERSAL//WARFARIN REVERSAL
7 12229 VENOUS THROMBOEMBOLISM//DEEP VEIN THROMBOSIS//VENOUS THROMBOSIS
8 11565 DIALYSIS DISEQUILIBRIUM SYNDROME//UREMIC ENCEPHALOPATHY//WARFARIN RELATED NEPHROPATHY
9 1794 ATRIAL FIBRILLATION//ATRIAL REMODELING//ELECTRICAL REMODELING
10 8566 BRIDGING THERAPY//BRIDGING ANTICOAGULATION//PERIOPERATIVE ANTICOAGULATION

Go to start page